Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

U M Zanger

Showing results (31-40 of 57) with videos related to

Pageof 6
Sort By:
Leukemia|July 2, 2003
A novel TPMT missense mutation associated with TPMT deficiency in a 5-year-old boy with ALLE Schaeffeler, M Stanulla, J Greil, et al.
The Pharmacogenomics Journal|October 19, 2011
Genomics of ADME gene expression: mapping expression quantitative trait loci relevant for absorption, distribution, metabolism and excretion of drugs in human liverA Schröder, K Klein, S Winter, et al.
The Journal of Biological Chemistry|October 5, 1990
Sequence requirements for cytochrome P-450IID1 catalytic activity. A single amino acid change (Ile380 Phe) specifically decreases Vmax of the enzyme for bufuralol but not debrisoquine hydroxylationE Matsunaga, T Zeugin, U M Zanger, et al.
The Journal of Steroid Biochemistry and Molecular Biology|January 6, 2012
Comparison of cAMP-responsive DNA sequences and their binding proteins associated with expression of the bovine CYP17 and CYP11A and human CYP21B genesM R Waterman, N Kagawa, U M Zanger, et al.
Lancet (London, England)|August 15, 2001
Frequency of C3435T polymorphism of MDR1 gene in African peopleE Schaeffeler, M Eichelbaum, U Brinkmann, et al.
Pharmacogenetics|October 23, 2001
Comprehensive analysis of the genetic factors determining expression and function of hepatic CYP2D6U M Zanger, J Fischer, S Raimundo, et al.
Journal of Inherited Metabolic Disease|January 26, 2006
Comprehensive analysis of pyrimidine metabolism in 450 children with unspecific neurological symptoms using high-pressure liquid chromatography-electrospray ionization tandem mass spectrometryC Schmidt, U Hofmann, D Kohlmüller, et al.
Biochemistry|September 5, 1989
The CYP2D gene subfamily: analysis of the molecular basis of the debrisoquine 4-hydroxylase deficiency in DA ratsE Matsunaga, U M Zanger, J P Hardwick, et al.
Clinical Pharmacology and Therapeutics|January 1, 1990
Polymorphic formation of morphine from codeine in poor and extensive metabolizers of dextromethorphan: relationship to the presence of immunoidentified cytochrome P-450IID1O Mortimer, K Persson, M G Ladona, et al.
Pharmacogenetics|March 25, 1998
Assessment of the predictive power of genotypes for the in-vivo catalytic function of CYP2D6 in a German populationE U Griese, U M Zanger, U Brudermanns, et al.
Pageof 6

Showing results (31-40 of 57) with videos related to

Sort By:
Pageof 6
Leukemia|July 2, 2003
A novel TPMT missense mutation associated with TPMT deficiency in a 5-year-old boy with ALLE Schaeffeler, M Stanulla, J Greil, et al.
The Pharmacogenomics Journal|October 19, 2011
Genomics of ADME gene expression: mapping expression quantitative trait loci relevant for absorption, distribution, metabolism and excretion of drugs in human liverA Schröder, K Klein, S Winter, et al.
The Journal of Biological Chemistry|October 5, 1990
Sequence requirements for cytochrome P-450IID1 catalytic activity. A single amino acid change (Ile380 Phe) specifically decreases Vmax of the enzyme for bufuralol but not debrisoquine hydroxylationE Matsunaga, T Zeugin, U M Zanger, et al.
The Journal of Steroid Biochemistry and Molecular Biology|January 6, 2012
Comparison of cAMP-responsive DNA sequences and their binding proteins associated with expression of the bovine CYP17 and CYP11A and human CYP21B genesM R Waterman, N Kagawa, U M Zanger, et al.
Lancet (London, England)|August 15, 2001
Frequency of C3435T polymorphism of MDR1 gene in African peopleE Schaeffeler, M Eichelbaum, U Brinkmann, et al.
Pharmacogenetics|October 23, 2001
Comprehensive analysis of the genetic factors determining expression and function of hepatic CYP2D6U M Zanger, J Fischer, S Raimundo, et al.
Journal of Inherited Metabolic Disease|January 26, 2006
Comprehensive analysis of pyrimidine metabolism in 450 children with unspecific neurological symptoms using high-pressure liquid chromatography-electrospray ionization tandem mass spectrometryC Schmidt, U Hofmann, D Kohlmüller, et al.
Biochemistry|September 5, 1989
The CYP2D gene subfamily: analysis of the molecular basis of the debrisoquine 4-hydroxylase deficiency in DA ratsE Matsunaga, U M Zanger, J P Hardwick, et al.
Clinical Pharmacology and Therapeutics|January 1, 1990
Polymorphic formation of morphine from codeine in poor and extensive metabolizers of dextromethorphan: relationship to the presence of immunoidentified cytochrome P-450IID1O Mortimer, K Persson, M G Ladona, et al.
Pharmacogenetics|March 25, 1998
Assessment of the predictive power of genotypes for the in-vivo catalytic function of CYP2D6 in a German populationE U Griese, U M Zanger, U Brudermanns, et al.
Pageof 6